DELAYED UPDATE — ResMed reports FY2026 revenue up 8% and launches $450M ASR
ResMed reported fiscal 2026 revenue of $5.7B, up 8% YoY, citing margin expansion and strong buybacks. It started a $450M accelerated repurchase using cash and MatrixCare sale proceeds and guided to higher fiscal 2027 revenue and EPS.